Oslo University Hospital HF — Sponsor Intelligence | 73 EU Trials

Filter these 73 trials by condition, phase, country and more.

Open in Search →

73 Registered trials

37 Recruiting

27 Completed trials

20 Countries active

140 Unique IMPs

100% Results reported

Phase III

Phase II

Phase IV

Phase III: 12 Phase II/III: 4 Phase II: 28 Phase I/II: 5 Phase III/IV: 1 Phase IV: 18 Phase I: 2 Phase I (Other): 2 Phase I (FiH): 1

Oversight events:

4 serious breaches 20 temporary halts 4 urgent safety measures across 8 trials

View oversight register →

100%

27 of 27 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Glioblastoma 3 Glioblastoma multiforme 2 Ischaemic stroke 2 Heart disease congenital 1 Pleural mesothelioma malignant 1 Aortic stenosis 1 Follicle centre lymphoma follicular grade I II III 1 Mitral valve prolapse 1 Colorectal cancer metastatic 1 Malignant melanoma stage III 1 Soft tissue sarcoma 1 Breast cancer 1

Top IMPs

SODIUM CHLORIDE 9 DEXAMETHASONE 4 MYCOPHENOLATE MOFETIL 3 NIVOLUMAB 3 TACROLIMUS 3 ATEZOLIZUMAB 2 BEVACIZUMAB 2 DABRAFENIB 2 FLOXURIDINE 2 GEMCITABINE 2 NEPAFENAC 2 OXYTOCIN SYNTHETIC 2

All trials — page 2

73 total

Intrathecal MRI Contrast for Assessment of CSF Transport Recruiting

2024-519936-18-00 Phase IV 1 country
A pilot study for optimizing meropenem administration in the intensive care unit – short six times vs. prolonged three times courses daily Recruiting

2024-520030-30-00 Phase III 1 country
Normothermic intraperitoneal chemotherapy – long term in peritoneal metastases from colorectal cancer – feasibility study Recruiting

2023-510217-26-00 Phase I (Other) 1 country
MOVE-JIA trial Recruiting

2024-513017-12-00 Phase IV 1 country
NeoLIPA: Neoadjuvant LTX-315 in combination with pembrolizumab in resectable stage III/IV melanoma Recruiting

2023-508649-42-00 Phase II 1 country RUXOTEMITIDE
Alpha 2 adrenergic receptor agonists for the prevention of delirium and cognitive decline after open heart surgery (ALPHA2PREVENT): randomis… Recruiting

2023-510212-39-00 Phase III/IV 1 country
Improved breast cancer therapy (I-BCT-1) in the neoadjuvant and metastatic setting: A phase 2 clinical trial protocol studying biological ra… Recruiting

2024-515087-31-00 Phase I/II 1 country CARBOPLATIN
Can Dapagliflozin Preserve Structure and Function in Transplanted Kidneys? Recruiting

2023-510485-27-00 Phase IV 1 country
COMBINATORY IMMUNOTHERAPY-2 (COM-IT-2) A phase 2 randomised open two-arm study to assess the tolerability and efficacy of immunotherapy comb… Recruiting

2023-510089-28-00 Phase I/II 1 country ATEZOLIZUMAB; CEMIPLIMAB; NIVOLUMAB; PEMBROLIZUMAB
Immunosuppressive Drugs and Gut Microbiome: Pharmacokinetic- and Microbiome Diversity Effects Recruiting

2023-510486-10-00 Phase IV 1 country MYCOPHENOLATE MOFETIL; TACROLIMUS
Trans-arterial treatment of patients with intra-hepatic cholangiocarcinoma not amenable to resection (TOMCAT) Recruiting

2023-504433-50-00 Phase IV 1 country FLOXURIDINE
Imaging multiple myeloma patients in the REMNANT study with Fluciclovine PET/CT (FLUCIPET) Recruiting

2024-517095-38-00 Phase II/III 1 country FLUCICLOVINE (18F)
Individualized Systems Medicine strategy to target cancer stem cells in patients with recurrent Glioblastoma (ISM-GBM) Recruiting

2023-510214-11-00 Phase I (Other) 1 country GEMCITABINE
Effect and safety of flecainide and metoprolol alene to suppress ventricular arrhythmias in arrhythmic mitral valve prolapse. Recruiting

2022-500814-24-00 Phase III 1 country
A randomized clinical two-arm trial comparing inflammation and cystoid macular edema for the medication regimens postoperative topical NSAID… Recruiting

2023-510091-31-00 Phase IV 1 country DEXAMETHASONE; NEPAFENAC
EVIDENT Recruiting

2023-510092-62-00 Phase II 1 country ALECTINIB; BINIMETINIB; CRIZOTINIB; DASATINIB; EVEROLIMUS; GEMCITABINE; IDELALIS…
NeoAdjuvant PErsonalized therapy in Estrogen Receptor positive breast cancer (NAPEER) - An open label phase II trial of endocrine treatment… Recruiting

2023-510093-13-00 Phase II 1 country BEVACIZUMAB; CAPIVASERTIB
Pre- vs. postoperative thromboprophylaxis for liver resection – a prospective, multicentre, randomized controlled trial (PREPOSTEROUS trial) Recruiting

2024-519726-20-00 Phase IV 1 country
Improving public cancer care by implementing precision medicine in Norway Recruiting

2023-507894-16-00 Phase II 1 country ALECTINIB HYDROCHLORIDE; ALPELISIB; ATEZOLIZUMAB; BEVACIZUMAB; CAPMATINIB; COBIM…
Sequential neoadjuvant ifosfamide and doxorubicin in localized high-grade soft tissue sarcoma of extremities and trunk wall Recruiting

2023-510185-27-00 Phase II 1 country DOXORUBICIN HYDROCHLORIDE; IFOSFAMIDE
Study to evaluate the therapeutic effect of a cell based immune therapy targeting cancer stem cells i the malignant brain tumor glioblastoma… Recruiting

2024-518663-35-00 Phase II/III 1 country TEMOZOLOMIDE
The Norwegian Antibiotics for Pneumonia in Children (NAPIC) Study Recruiting

2024-512001-39-01 Phase IV 1 country AMOXICILLIN TRIHYDRATE
Nordic Pancreatic Cancer Trial (NORPACT) – 1 Recruiting

2024-517719-65-00 Phase II 2 countries
SAFETY AND FEASIBILITY OF IRRADIATION AND NIVOLUMAB IN ESOPHAGEAL CANCER (INEC-STUDY) – A PHASE I/II TRIAL Ended

2023-510124-77-01 Phase I/II 1 country NIVOLUMAB

Showing 25–48 of 73 trials

← All sponsors A–Z